Abnova (Taiwan) Corporation operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Abnova (Taiwan) with three other
companies in this sector in TAIWAN :
Genmont Biotech Inc
sales of 325.19 million Taiwanese Dollars [US$11.63 million]
of which 100%
was Jingyue Company),
(806.58 million Taiwanese Dollars [US$28.85 million]
Mycenax Biotech Incorporated
(665.34 million Taiwanese Dollars [US$23.80 million]
of which 68%
was Technical Service Income).
During the year ended December of 2020, sales at
Abnova (Taiwan) were 456.45 million Taiwanese Dollars (US$16.33 million).
increase of 10.2%
versus 2019, when the company's sales were 414.16 million Taiwanese Dollars .
The sales level in 2020 was fairly close to the level five years ago: in 2015, Abnova (Taiwan) had sales
of 451.37 million Taiwanese Dollars .
Sales of Paired Antibodies saw an increase
that was more than double the company's growth rate: sales were up
109.4% in 2020, from
77.45 million Taiwanese Dollars to 162.16 million Taiwanese Dollars .
Not all segments of Abnova (Taiwan) experienced an increase in sales in 2020:
sales of Equipment fell 92.1% to 827,000.00 Taiwanese Dollars .
(However, this segment's sales were only a very small portion of the company's overall sales).
Abnova (Taiwan) also experienced decreases in sales in
Monoclonal Antibodies (down 10.6% to 115.04 million Taiwanese Dollars )
Others (down 2.9% to 88.42 million Taiwanese Dollars )
Protein (down 12.2% to 56.63 million Taiwanese Dollars )
Multiple Strains of Antibodies (down 20.6% to 33.37 million Taiwanese Dollars )